Evidence map›Paper›PMID 35569509›Full record

ArticleThe Journal of biological chemistry2022

Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression.

DeannaLee M Beauvais, Scott E Nelson, Kristin M Adams, Noah A Stueven, Oisun Jung, Alan C Rapraeger

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. SDC1 is a critical transmembrane proteoglycan in breast cancer.World journal of surgical oncology · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

DeannaLee M BeauvaisDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Scott E NelsonDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Kristin M AdamsDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Noah A StuevenDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Oisun JungDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Alan C RapraegerDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA. Electronic address: rapraeger@humonc.wisc.edu.
University of Wisconsin–Madison · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI HARARI, PAUL M · 2016 to 2020
$10.8M
Signaling role of syndecans in HER2+ and triple negative breast cancerR01CA163662 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI RAPRAEGER, ALAN C · 2013 to 2017
$2.0M
A kinase-independent role for EGFR in p38MAPK suppression and S-phase progression in head and neck cancerR01DE028341 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI RAPRAEGER, ALAN C · 2020 to 2022
$1.4M
NCI NIH HHS P30 CA013148NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA163662NIDCR NIH HHS P50 DE026787NIDCR NIH HHS R01 DE028341
6 · The paper itself

Abstract

Epidermal growth factor receptor (EGFR) is a causal factor in carcinoma, yet many carcinoma patients are resistant to EGFR inhibitors. Potential insight into this resistance stems from prior work that showed EGFR in normal epithelial cells docks to the extracellular domain of the plasma membrane proteoglycan syndecan-4 (Sdc4) engaged with α3β1 and α6β4 integrins. We now report that this receptor complex is modified by the recruitment of syndecan-2 (Sdc2), the Recepteur d'Origine Nantais (RON) tyrosine kinase, and the cellular signaling mediator Abelson murine leukemia viral oncogene homolog 1 (ABL1) in triple-negative breast carcinoma and head and neck squamous cell carcinoma, where it contributes to EGFR kinase-independent proliferation. Treatment with a peptide mimetic of the EGFR docking site in the extracellular domain of Sdc4 (called SSTN

Indexed as

CarcinomaCell CycleErbB ReceptorsReceptor Protein-Tyrosine KinasesSyndecan-2Syndecan-4Cell MembraneHumansp38 Mitogen-Activated Protein KinasesProto-Oncogene Proteins c-ablABL1 protein, humanEGFR protein, humanErbB Receptorsp38 Mitogen-Activated Protein KinasesProto-Oncogene Proteins c-ablReceptor Protein-Tyrosine KinasesRON proteinSDC2 protein, humanSDC4 protein, humanSyndecan-2Syndecan-4Abl tyrosine kinasebreast cancercell cycleepidermal growth factor receptor (EGFR)head and neck cancerintegrinmacrophage stimulating receptor (MST1R)p38MAPKRecepteur d’Origine Nantais (RON)syndecan

Identifiers

PMID35569509
PMCPMC9190016
OpenAlexW4280517879

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.